Get started
Author

Sarah LeNoir Sammons

Observed names: S L Sammons, S Sammons, S. L. Sammons, S. Sammons, S.L. Sammons, Sammons, Sarah, Sammons, Sarah L, Sarah L. Sammons, Sarah L Sammons, Sarah L. Sammons, Sarah Sammons
Observed institutions: University of North Carolina at Chapel Hill, University of Maryland, Baltimore, Christiana Care Health System, Brigham and Women's Hospital, University of Maryland Medical Center, Harvard University, Duke University, University of Vermont Medical Center, Nanostring Technologies (United States), Christiana Hospital, Dana-Farber Cancer Institute, Duke Medical Center, Dana-Farber/Harvard Cancer Center, Duke University Hospital, Dana-Farber Brigham Cancer Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Duke Cancer Institute
ORCID: 0000-0003-2589-9422
Observed ORCID: 0000-0003-2589-9422
OpenAlex ID: A5013516632
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
2019 · Li Zhu, Jessica L. Narloch, et al. · Journal for ImmunoTherapy of Cancer · 113
PDF
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
2022 · Sheheryar Kabraji, Jing Ni, et al. · Clinical Cancer Research · 102
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
2024 · Kevin Kalinsky, Giampaolo Bianchini, et al. · Journal of Clinical Oncology · 93
PDF
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
2017 · Sarah L. Sammons, Donna L. Topping, et al. · Current Cancer Drug Targets · 86
PDF
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
2024 · Kevin Kalinsky, Giampaolo Bianchini, et al. · Journal of Clinical Oncology · 76
PDF
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
2023 · M.P. Goetz, N.A. Bagegni, et al. · Annals of Oncology · 61
PDF
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
2025 · David R Gandara, Neeraj Agarwal, et al. · Journal for ImmunoTherapy of Cancer · 57
PDF
Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients
2021 · Mahsa Taskindoust, Samantha M. Thomas, et al. · Annals of Surgical Oncology · 57
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
2023 · Laura Alder, Dario Trapani, et al. · npj Breast Cancer · 51
PDF
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
2023 · Romualdo Barroso-Sousa, Jana Priscila Pacífico, et al. · Cancers · 50
PDF
Freedom From Local and Regional Failure of Contralateral Neck With Ipsilateral Neck Radiotherapy for Node-Positive Tonsil Cancer: Results of a Prospective Management Approach
2009 · Kyle E. Rusthoven, David Raben, et al. · International Journal of Radiation Oncology*Biology*Physics · 49
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 48
PDF
The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor
2020 · Kaitlyn J. Andreano, Jennifer G. Baker, et al. · Molecular Cancer Therapeutics · 44
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
2024 · Tira J. Tan, Sarah Sammons, et al. · Clinical Cancer Research · 42
PDF
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
2022 · Komal L. Jhaveri, Rinath Jeselsohn, et al. · Journal of Clinical Oncology · 41
Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis
2017 · Jessica L Narloch, S. Harrison Farber, et al. · Neuro-Oncology · 41
PDF
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
2023 · Abhenil Mittal, Consolacion Molto Valiente, et al. · Cancers · 39
PDF
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3‐ITD acute myeloid leukemia prior to stem cell transplant and after relapse post‐transplant
2014 · Sarah L. Sammons, Keith W. Pratz, et al. · American Journal of Hematology · 38
PDF
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
2021 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 36
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype
2018 · Jeremy Force, Lynn J. Howie, et al. · Clinical Breast Cancer · 33
Copper Suppression as Cancer Therapy: The Rationale for Copper Chelating Agents in BRAF V600 Mutated Melanoma
2016 · Sarah Sammons, Donita Brady, et al. · Melanoma Management · 32
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2− Breast Cancer
2019 · Sarah Sammons, Mythili Shastry, et al. · Clinical Breast Cancer · 28
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer
2024 · K. Fanucci, A. Giordano, et al. · ESMO Open · 24
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data
2020 · Louis E. Fernandes, Caroline G. Epstein, et al. · Clinical Breast Cancer · 24
PDF
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
2018 · Sarah Sammons, Noah S. Kornblum, et al. · Targeted Oncology · 24
PDF
Works count: 241
Citation count: 1,903
H-index: 24
I10-index: 50
Year
Topic
Type